Literature DB >> 350249

Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.

R Gugler, G Mueller.   

Abstract

1 Based on the Scatchard plot of the binding data of valproic acid (VPA) it is concluded that the drug is bound by two groups of binding sites with the association constants K1=40.0 X 10(-3) and K2=0.39 X 10(3), and the number of binding sites n1=1.5 and n2=6.8. 2 The binding is dependent on dialysis time, on temperature, on the drug concentration, and on the protein concentration in plasma. 3 At therapeutic plasma concentrations unbound VPA is 8.4 +/- 2.5%, but is increased to 20.3 +/- 4.7% in patients with significant impairment of renal function (P less than 0.001). 4 In patients with renal disease a good correlation is found between unbound VPA and serum creatinine, creatinine clearance, blood nitrogen and uric acid, respectively. A poor correlation is seen between unbound VPA and total protein or albumin concentration in plasma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350249      PMCID: PMC1429355          DOI: 10.1111/j.1365-2125.1978.tb01652.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

2.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

3.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

4.  Pharmacokinetic consequences of plasma protein binding of drugs.

Authors:  P T Schoenemann; D W Yesair; J J Coffey; F J Bullock
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

5.  Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants.

Authors:  A Rane; P K Lunde; B Jalling; S J Yaffe; F Sjöqvist
Journal:  J Pediatr       Date:  1971-05       Impact factor: 4.406

6.  Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.

Authors:  G D Olsen; W M Bennett; G A Porter
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

Review 7.  Drug therapy. Binding of drugs to serum albumin (second of two parts).

Authors:  J Koch-Weser; E M Sellers
Journal:  N Engl J Med       Date:  1976-03-04       Impact factor: 91.245

Review 8.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 9.  Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review.

Authors:  D Simon; J K Penry
Journal:  Epilepsia       Date:  1975-11       Impact factor: 5.864

10.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

View more
  25 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 3.  Methodological aspects of the evaluation of the binding of drugs to plasma and tissue proteins.

Authors:  J P Tillement; E Albengres; S Urien
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Valproic acid fails to displace phenobarbitone and carbamazepine from plasma protein binding sites in epileptic patients.

Authors:  F Pisani; G Oteri; R Di Perri
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

7.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

8.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

10.  Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.

Authors:  W G Rapeport; A D Mendelow; G French; P MacPherson; E Teasdale; E Agnew; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.